ART Bioscience

Company Type: Therapeutic development

Main focus: Advancing novel genetic therapies to treat genetic musculoskeletal system disorders

Company stage: Pre-clinical

Diseases: Duchenne muscular dystrophy and other genetic musculoskeletal system disorders

Genome-editing tool: CRISPR-Cas9

Funding stage: Unknown

Location: Rehevot, HaMerkaz, Israel

Website: https://www.artbioscience.com/

Pipeline: www.artbioscience.com/pipeline

Partners:

ART Bioscience is a pre-clinical stage biotechnology company focused on developing mRNA-based therapies for rare diseases, with a primary focus on duchenne muscular dystrophy (DMD). The company uses mRNA therapy and gene editing based on CRISPR-Cas9 technology to target genetic variants responsible for DMD. ART Bioscience aims to offer therapies based on protein replacement and gene editing to restore functional dystrophin protein in patients. The company’s pipeline consists of three investigational therapeutics for DMD involving mRNA therapy and gene-editing platforms.